Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recifercept Open-Label Extension in Children with Achondroplasia
NCT05116046Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Dec 2021
- Primary completion
- Dec 2022
- Modality
- Fc-Fusion Proteins
- Countries
- 7
01
Overview
Phase 2, open-label trial of recifercept in achondroplasia (ACH) (3 arms), sponsored by Pfizer. Primary endpoints: Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Severe AEs up to 11 months and Change From Baseline in Height at Month 24. Started Dec 2021; status: terminated.
02
Drugs
recifercept
03
Conditions
achondroplasia (ACH)
Beyond the preview
Go deeper on NCT05116046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05116046.